Gracell Biotechnologies Inc logo

Gracell Biotechnologies Inc Share Price Today (NASDAQ: GRCL)

Gracell Biotechnologies Inc share price is $0 & ₹0.00 as on 20 Feb 2024 IST

▲

-10.25

(-100%)

Market is closed - opens 7 PM, 07 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 21 Feb 2024

View live Gracell Biotechnologies Inc share price in Dollar and Rupees. Guide to invest in Gracell Biotechnologies Inc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Gracell Biotechnologies Inc, along with analyst recommendations, forecasts, and comprehensive financials.

Gracell Biotechnologies Inc (GRCL) Key Statistics

in dollars & INR

Previous Close
$10.25
Open
$10.26
Market Capitalization
$989.9M
Today's Volume
$6.4M
Revenue TTM
$0.0
EBITDA
$-509.6M
Earnings Per Share (EPS)
$-0.97
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-31.57%

How to invest in Gracell Biotechnologies Inc Stock (GRCL) from India?

It is very easy for Indian residents to invest directly in Gracell Biotechnologies Inc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gracell Biotechnologies Inc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Gracell Biotechnologies Inc or GRCL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gracell Biotechnologies Inc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gracell Biotechnologies Inc shares which would translate to null fractional shares of Gracell Biotechnologies Inc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Gracell Biotechnologies Inc, in just a few clicks!

Global Institutional Holdings in Gracell Biotechnologies Inc

  • Vivo Capital, LLC

    11.27%

  • Temasek Holdings Ltd.

    10.25%

  • Orbimed Advisors, LLC

    9.64%

  • Hudson Bay Capital Management LP

    4.14%

  • TCG Crossover Management, LLC

    3.15%

  • Logos Global Management LP

    2.61%

Analyst Recommendation on Gracell Biotechnologies Inc

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Gracell Biotechnologies Inc(by analysts ranked 0 to 5 stars)

About Gracell Biotechnologies Inc

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.
Organization
Gracell Biotechnologies Inc
Employees
314
CEO
Dr. Wei Cao BM, Ph.D.
Industry
Miscellaneous

Important FAQs about investing in GRCL Stock from India :

Can Indians buy Gracell Biotechnologies Inc shares?

Yes, Indians can invest in the Gracell Biotechnologies Inc (GRCL) from India.

With INDmoney, you can buy Gracell Biotechnologies Inc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Gracell Biotechnologies Inc at zero transaction cost.

How can I buy Gracell Biotechnologies Inc shares from India?

It is very easy to buy Gracell Biotechnologies Inc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gracell Biotechnologies Inc (GRCL) be purchased?

Yes, you can buy fractional shares of Gracell Biotechnologies Inc with INDmoney app.

What are the documents required to start investing in Gracell Biotechnologies Inc stocks?

To start investing in Gracell Biotechnologies Inc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Gracell Biotechnologies Inc?

Today's market capitalisation of Gracell Biotechnologies Inc GRCL is 989.9M

Who is the Chief Executive Officer (CEO) of Gracell Biotechnologies Inc ?

Dr. Wei Cao BM, Ph.D. is the current Chief Executive Officer (CEO) of Gracell Biotechnologies Inc.